T. Rowe Price Associates
NVCT icon

T. Rowe Price Associates’s Nuvectis Pharma NVCT Stock Holding History

T. Rowe Price Associates’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Buy
13,805
+1,757
+15% +$19.7K ﹤0.01% 2914
2026
Q1 		$94K Buy
+12,048
New +$103K ﹤0.01% 3012

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

T. Rowe Price Associates's NVCT Position: Q2 2026 in Review

T. Rowe Price Associates increased its Nuvectis Pharma (NVCT) stake by 15% in Q2 2026, buying an estimated $19.7K and bringing the position to 13,805 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #2914.

T. Rowe Price Associates first reported a position in NVCT in Q1 2026 and has held it in 2 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • T. Rowe Price Associates held 13,805 shares of Nuvectis Pharma worth $254K as of Q2 2026.
  • T. Rowe Price Associates bought 1,757 Nuvectis Pharma shares in Q2 2026, an estimated $19.7K.
  • Nuvectis Pharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2914 holding.
  • T. Rowe Price Associates first reported a position in Nuvectis Pharma in Q1 2026 and has held it in 2 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.